桥前池鞘内药物输注系统治疗难治性颅面部癌痛:多中心回顾性研究
该多中心回顾性研究纳入33例原发或转移性颅面部癌痛患者,将鞘内吗啡泵导管置入桥前池。术后第1、7、30天NRS评分均显著低于术前,爆发痛次数进行性减少,全身吗啡当量剂量显著降低,约78.8%和96.7%的患者在术后第1天和第30天疼痛缓解>50%,不良事件少且无严重不良事件。
要点
- 桥前池鞘内吗啡泵置管可显著降低颅面部癌痛患者NRS评分和爆发痛次数。
- 术后全身吗啡当量剂量显著减少,第7天和第30天中位数为0 mg·d⁻¹。
- 不良事件少,无严重不良事件,可作为难治性颅面部癌痛的考虑选项。
核心结论
- 将鞘内吗啡泵导管尖端置入桥前池可有效缓解难治性颅面部癌痛,吗啡总剂量需求极低且不良事件少。
研究设计与样本
- 采用Friedman检验和配对符号秩检验比较术前与术后第1、7、30天的NRS评分、爆发痛次数、鞘内吗啡剂量及全身吗啡当量剂量,P值用Bonferroni校正。
主要发现
- 术后第1、7、30天NRS评分中位数(IQR)分别为2.0(1.0-3.5)、2.0(1.0-2.0)、1.0(1.0-2.0),均显著低于术前8.0(7.0-10.0)(均P < .001)。
- 术后第1、7、30天爆发痛次数/d中位数(IQR)分别为1.0(0.0-3.0)、2.0(0.0-3.0)、0.0(0.0-1.2),均显著低于基线6.0(4.5-10.0)(均P < .001)。
- 约78.8%和96.7%的患者在术后第1天和第30天报告疼痛缓解>50%;与术后第1天相比,术后第30天疼痛缓解>75%的患者比例随持续鞘内治疗而增加。
- 全身吗啡当量剂量中位数(IQR)从基线228 mg·d⁻¹(120-408 mg·d⁻¹)降至术后第1天0(0-120)mg·d⁻¹(P = .001),术后第7天和第30天均为0(0-0)mg·d⁻¹(均P < .001)。
- 少数患者报告围术期不良事件,包括恶心、便秘、低血压、尿潴留、口干、头痛和镇静;无严重不良事件发生。
临床怎么用
- 对于严重难治性颅面部癌痛患者,可考虑将鞘内吗啡泵导管尖端置入桥前池以有效镇痛并减少全身阿片类药物用量。
局限性
- 本研究为回顾性研究,样本量较小(33例),证据级别有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with craniofacial cancer frequently suffer from severe pain. The traditional intrathecal, oral, or intravenous analgesics could only provide insufficient pain relief with many side effects. Thus, a more effective analgesia approach is required. This study aimed to investigate the safety and efficacy of placing the catheter of an intrathecal morphine pump in the prepontine cistern for the treatment of craniofacial cancer pain. METHODS: We performed a retrospective study of patients with primary or metastatic craniofacial cancer pain who received the catheter placement of an intrathecal morphine pump into the prepontine cistern in eleven medical centers from September 2019 to December 2023. Friedman test and pairwise signed-rank test were used to evaluate the difference in numeric rating scale (NRS) scores, the number of breakthrough pain episodes, dose of intrathecal morphine, and dose of systemic morphine equivalents (oral, patch, intravenous) from preoperative period to postoperative days 1, 7, and 30. P values were corrected for multiple comparisons using Bonferroni test. RESULTS: The study included 33 patients. The median (interquartile range [IQR]) of NRS scores at days 1, 7, and 30 postimplant were 2.0 (1.0-3.5), 2.0 (1.0-2.0), and 1.0 (1.0-2.0), respectively, which was significantly lower than that before surgery (median, 8.0; IQR, 7.0-10.0; all P < .001). Compared to baseline number/d of breakthrough pain episodes (median, 6.0; IQR, 4.5-10.0), there was a progressive decrease in the number/d of breakthrough pain episodes at day 1, day 7, and day 30 postimplant, and the median (IQR) were 1.0 (0.0-3.0), 2.0 (0.0-3.0), and 0.0 (0.0-1.2), respectively (all P < .001). Approximately 78.8% and 96.7% of patients reported pain relief >50% at days 1 and 30 postimplant, respectively. Compared with that at day 1 postimplant, the proportion of patients with a pain relief rate >75% at day 30 postimplant also increased with continued intrathecal treatment. Compared to the dose of baseline systemic morphine equivalents (median, 228 mg.d -1 ; IQR, 120-408 mg.d -1 ), the dose of systemic morphine equivalents reduced significantly from 0(0-120) mg.d -1 at day 1 postimplant ( P = .001), to 0 (0-0) mg.d -1 at days 7 and 30 postimplant (both P < .001). Few patients reported perioperative adverse events, including nausea, constipation, hypotension, urinary retention, dry mouth, headache, and sedation. No severe adverse events occurred. CONCLUSIONS: Placing the catheter tip of an intrathecal morphine pump into the prepontine cistern could effectively relieve refractory craniofacial cancer pain with an extremely low total morphine dose requirement and few adverse events. This procedure could be considered in patients with severe refractory craniofacial cancer pain.
引用
- Long D, Li X, Zhang Y, et al. Intrathecal Drug Delivery System in Prepontine Cistern for Patients with Intractable Craniofacial Cancer Pain: A Multicenter Retrospective Study. Anesth Analg. 2024. PMID: 39259695. doi:10.1213/ANE.0000000000007262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。